Log in

NYSE:CRL - Charles River Laboratories Intl. Stock Price, Forecast & News

$146.23
+1.53 (+1.06 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$145.77
Now: $146.23
$146.94
50-Day Range
$126.74
MA: $136.36
$147.01
52-Week Range
$103.00
Now: $146.23
$149.07
Volume284,970 shs
Average Volume355,406 shs
Market Capitalization$7.14 billion
P/E Ratio24.25
Dividend YieldN/A
Beta1.11
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.27 billion
Cash Flow$9.55 per share
Book Value$27.37 per share

Profitability

Net Income$226.37 million

Miscellaneous

Employees14,700
Market Cap$7.14 billion
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.


Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) announced its quarterly earnings data on Wednesday, November, 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.64 by $0.05. The medical research company earned $668 million during the quarter, compared to analysts' expectations of $674.08 million. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. The firm's revenue was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.53 EPS. View Charles River Laboratories Intl.'s Earnings History.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Charles River Laboratories Intl..

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. updated its third quarter 2019 earnings guidance on Monday, October, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $665-670 million, compared to the consensus revenue estimate of $677.8 million.

What price target have analysts set for CRL?

12 analysts have issued 12 month target prices for Charles River Laboratories Intl.'s stock. Their forecasts range from $138.00 to $170.00. On average, they expect Charles River Laboratories Intl.'s stock price to reach $154.78 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Charles River Laboratories Intl..

What is the consensus analysts' recommendation for Charles River Laboratories Intl.?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..

Has Charles River Laboratories Intl. been receiving favorable news coverage?

Headlines about CRL stock have trended extremely positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Charles River Laboratories Intl. earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Charles River Laboratories Intl..

Are investors shorting Charles River Laboratories Intl.?

Charles River Laboratories Intl. saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 939,900 shares, a decrease of 26.6% from the October 31st total of 1,280,000 shares. Based on an average trading volume of 320,900 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.0% of the shares of the company are sold short. View Charles River Laboratories Intl.'s Current Options Chain.

Who are some of Charles River Laboratories Intl.'s key competitors?

What other stocks do shareholders of Charles River Laboratories Intl. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include Celgene (CELG), Boeing (BA), Intel (INTC), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Alibaba Group (BABA), Emerson Electric (EMR), Procter & Gamble (PG), Biogen (BIIB) and Cisco Systems (CSCO).

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the folowing people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
  • Mr. David P. Johst, Corp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer (Age 57)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.35%), TimesSquare Capital Management LLC (2.06%), Congress Asset Management Co. MA (1.40%), Voya Investment Management LLC (1.23%), First Trust Advisors LP (1.19%) and Fisher Asset Management LLC (0.90%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

Which major investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Copper Rock Capital Partners LLC, State Street Corp, Fisher Asset Management LLC, Man Group plc, SG Americas Securities LLC, Congress Asset Management Co. MA and Great West Life Assurance Co. Can. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David Ross Smith, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

Which major investors are buying Charles River Laboratories Intl. stock?

CRL stock was bought by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, TimesSquare Capital Management LLC, Endurant Capital Management LP, Massachusetts Financial Services Co. MA, Voya Investment Management LLC, Monarch Partners Asset Management LLC, Trinity Street Asset Management LLP and Tygh Capital Management Inc.. View Insider Buying and Selling for Charles River Laboratories Intl..

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $146.23.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $7.14 billion and generates $2.27 billion in revenue each year. The medical research company earns $226.37 million in net income (profit) each year or $6.03 on an earnings per share basis. Charles River Laboratories Intl. employs 14,700 workers across the globe.View Additional Information About Charles River Laboratories Intl..

What is Charles River Laboratories Intl.'s official website?

The official website for Charles River Laboratories Intl. is http://www.criver.com/.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories Intl. (NYSE CRL)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  449 (Vote Underperform)
Total Votes:  815
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel